Gene expression data of locally advanced rectal cancer patients by KRAS status. Gene expression data of locally advanced rectal cancer patients by KRAS status

Stromal and extracellular matrix related genes are downregulated in KRAS mutant rectal adenocarcinoma We used Affymetrix U133 platform to profile the differences in the transcriptome of KRAS-wild-type and KRAS-mutant rectal cancer specimens Overall design: RNA was extracted from 76 microsatellite stable pre-treatment biopsy samples from locally advanced rectal cancer patients accrued through the TIMING trial (ClinicalTrials.gov, number NCT00335816) and differential gene expression analysis was performed based on KRAS mutation status